Atherosclerosis and Lipoproteins |
From the Divisions of Cardiovascular Research (S.H.Z., G.F.E., J.A.S., P.I.E.) and Research Technology & Proteins (G.S.), Lilly Research Labs, DC0434, Indianapolis, Ind 46285.
Correspondence to Steven H. Zuckerman, Division of Cardiovascular Research, Lilly Research Labs, DC0434, Indianapolis, IN 46285. E-mail Zuckerman_Steven{at}Lilly.com
AbstractThe murine double
transgenic mouse expressing both human apoB100 and cholesteryl ester
transfer protein (CETP), has been used as a model to understand the
effects mediated by various therapeutic modalities on serum
lipoproteins and on atherosclerotic lesion progression. In the
present study the effects of estrogen therapy on serum lipoproteins
were investigated after mice were placed on an atherosclerotic diet.
The daily oral administration of 20 or 100 µg/kg of 17
-ethinyl
estradiol resulted in a significant, dose-dependent increase in LDL
cholesterol over a 20-week regimen. These differences were
apparent by 6 weeks and further increases were observed through the
20-week period. Although CETP did result in a reduction in total HDL,
estrogen did not have any impact on the amount of CETP activity
associated with the HDL particles. The significant increase in LDL
cholesterol was associated with increases in the amount of
apoB100 and B48 and apoEcontaining particles. Hepatic apoB message
levels, however, were not different between the experimental groups.
Although the extent of atherosclerotic lesions was modest, <0.5% of
the aortic surface area in the vehicle group, the high-dose estrogen
group, showed an increase in lesion area consistent with the
elevation in LDL cholesterol. These lesions, primarily
restricted to the aortic root and aortic semilunar valves, were more
intensely stained with Oil Red O in the high-dose estrogen group when
compared with the vehicle controls.
Key Words: estrogen apoproteins cholesterol lipoproteins transgenic
This article has been cited by other articles:
![]() |
M. Westerterp, C. C. van der Hoogt, W. de Haan, E. H. Offerman, G. M. Dallinga-Thie, J. W. Jukema, L. M. Havekes, and P. C.N. Rensen Cholesteryl Ester Transfer Protein Decreases High-Density Lipoprotein and Severely Aggravates Atherosclerosis in APOE*3-Leiden Mice Arterioscler Thromb Vasc Biol, November 1, 2006; 26(11): 2552 - 2559. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Casquero, J. A. Berti, A. G. Salerno, E. J. B. Bighetti, P. M. Cazita, D. F. J. Ketelhuth, M. Gidlund, and H. C. F. Oliveira Atherosclerosis is enhanced by testosterone deficiency and attenuated by CETP expression in transgenic mice J. Lipid Res., July 1, 2006; 47(7): 1526 - 1534. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. Cazita, J. A. Berti, C. Aoki, M. Gidlund, L. M. Harada, V. S. Nunes, E. C. R. Quintao, and H. C. F. Oliveira Cholesteryl ester transfer protein expression attenuates atherosclerosis in ovariectomized mice J. Lipid Res., January 1, 2003; 44(1): 33 - 40. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. B. Hodgin and N. Maeda Minireview: Estrogen and Mouse Models of Atherosclerosis Endocrinology, December 1, 2002; 143(12): 4495 - 4501. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |